Etanercept treatment in adults with established rheumatoid arthritis: 7 Years of clinical experience

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 854-861

  Moreland, Larry W ^a   Weinblatt, Michael E ^b   Keystone, Edward C ^c   Kremer, Joel M ^d   Martin, Richard W ^e   Schiff, Michael H ^f   Whitmore, James B ^g   White, Barbara W ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Center for Rheumatology LLP   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f Denver Arthritis Clinic PC   (United States)

^g AMGEN INC   (United States)

Author keywords

Etanercept; Longterm treatment; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ADD ON THERAPY; ADULT; AGED; ANGINA PECTORIS; AORTA RUPTURE; ARTICLE; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FRACTURE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; INFECTION; INFECTION RATE; LARYNX CARCINOMA; LISTERIOSIS; LONG TERM CARE; LUNG CANCER; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; MYOCARDITIS; NONHODGKIN LYMPHOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SKIN CANCER; SKIN INFECTION; SOFT TISSUE INFECTION; SQUAMOUS CELL CARCINOMA; SYNCOPE; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFECTION; JOINTS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646464514     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy [erratum appears in N Engl J Med 1990;323:996]. N Engl J Med 1990;322:1277-89.
2. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
3. Bendtsen P, Akerlind I, Hornquist JO. Assessment of quality of life in rheumatoid arthritis: methods and implications. Pharmacoeconomics 1994;5:286-98.
4. Scott DL. Pursuit of optimal outcomes in rheumatoid arthritis. Pharmacoeconomics 2004;22 Suppl:13-26.
5. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 2003;62 Suppl:ii2-ii9.
6. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
7. Klareskog L, van der Heijde DM, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
8. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
9. Breedveld F, Emery P, Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
10. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
11. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
12. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
13. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
14. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
15. Bathon J, Genovese M. The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003;Suppl 31:195-7.
16. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
17. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003;30:691-6.
18. Center for Drug Evaluation and Research. Coding symbols for a thesaurus of adverse reactions terms (COSTART). 3rd ed. Rockville, MD: Department of Health and Human Services; 1990.
19. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
20. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
21. van Riel PLCM. DAS-Score.NL. 2004; Available at: http://www.reuma- nijmegen.nl/www.das-score.nl. Accessed January 13, 2006.
22. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
23. Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999;42 Suppl:S242.
24. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
25. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973-1999) [11 Registries, 1992-1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission; 2002.
26. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997;133:735-40.
27. Harris RB, Griffith K, Moon TE. Trends in the incidence of non-melanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001;45:528-36.
28. Kochanek KD, Smith BL, Anderson RN. Deaths: preliminary data for 1999. National Vital Statistics Reports 2001;49:1-48.
29. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
30. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
31. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
32. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:148-58.
33. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
34. Etanercept (Enbrel®) safety review, March 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/3930S1_06_Amgen-Enbrel.ppt. Accessed January 13, 2006.
35. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.